1.
Cannabis and mental illness: a review
by Lowe, Darby J. E
European archives of psychiatry and clinical neuroscience, 2018, Vol.269 (1), p.107-120
2.
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
by Christensen, Robin, MSc
The Lancet (British edition), 2007, Vol.370 (9600), p.1706-1713
3.
Association of Megestrol Use With the Development of New Psychiatric Diagnoses
by Ramamurthy, Swetha
The American journal of geriatric psychiatry, 2020, Vol.28 (6), p.633-643
4.
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
by Nguyen, Alain
AIDS (London), 2011, Vol.25 (12), p.1481-1487
5.
Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat
by Paris, Jason J
Psychopharmacology, 2013, Vol.231 (11), p.2349-2360
6.
A blunted anxiolytic like effect of curcumin against acute lead induced anxiety in rat: Involvement of serotonin
by Benammi, Hind
Acta histochemica, 2014, Vol.116 (5), p.920-925
7.
De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C
by MARTÍN‐SANTOS, R.
Alimentary pharmacology & therapeutics, 2008, Vol.27 (3), p.257-265
8.
A randomized crossover study to compare efavirenz and etravirine treatment
by NGUYEN, Alain
AIDS (London), 2011, Vol.25 (1), p.57-63
9.
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C
by de Knegt, R. J
Alimentary pharmacology & therapeutics, 2011, Vol.34 (11-12), p.1306-1317
10.
Caffeine challenge test and panic disorder: a systematic literature review
by Vilarim, Marina Machado
Expert review of neurotherapeutics, 2011, Vol.11 (8), p.1185-1195
11.
Effects of chronic lead intoxication on rat serotoninergic system and anxiety behavior
by Sansar, Wafa
Acta histochemica, 2012, Vol.114 (1), p.41-45
12.
Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice
by BALERIO, Graciela N
Psychopharmacologia, 2005, Vol.181 (2), p.260-269
13.
Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C
by Malaguarnera, M
Journal of interferon & cytokine research, 2001, Vol.21 (5), p.273-278
14.
Psychiatric side effects during methysergide treatment
by Cittadini, E
Journal of neurology, neurosurgery and psychiatry, 2005, Vol.76 (7), p.1037-1038
15.
Dopaminergic Lateralisation in the Forebrain: Relations to Behavioural Asymmetries and Anxiety in Male Wistar Rats
by Thiel, C.M
Neuropsychobiology, 2001, Vol.43 (3), p.192-199
16.
The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety
by Cippitelli, Andrea
Alcohol (Fayetteville, N.Y.), 2011, Vol.45 (6), p.567-576
17.
Interferon-α in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated
by Bannink, Marjolein, M.D., Ph.D
Psychosomatics (Washington, D.C.), 2008, Vol.49 (1), p.56-63
18.
What is best for the patient?
by Harper, Adam
The Lancet (British edition), 2003, Vol.361 (9371), p.1831-1832
19.
Neurobehavioral Evaluation in Humans Exposed to Hydrocarbons: A New Statistical Approach
by Abbate, C
Psychotherapy and psychosomatics, 2001, Vol.70 (1), p.44-49
20.
Acute anxiety and depression induced by loss of sensation and muscle control after botulinum toxin A injection
by Brenner, R
Southern medical journal (Birmingham, Ala.), 1999, Vol.92 (7), p.738
